Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported first quarter EPS of $2.05, $0.08 better than the analyst estimate of $1.97. Revenue for the quarter came in at $11.3B versus the consensus estimate of $11.49B.
Guidance
Bristol-Myers Squibb sees FY 2023 EPS of $7.95-$8.25 versus the analyst consensus of $8.04.
Bristol-Myers Squibb's stock price closed at $68.02. It is down -6.11% in the last 3 months and down -11.89% in the last 12 months.
Bristol-Myers Squibb saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb's stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb's Financial Health score is "great performance".
Check out Bristol-Myers Squibb's recent earnings performance, and Bristol-Myers Squibb's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar